Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 10/20 | 0.79 |
| ▸ | PRKAG1 | P54619 | 10/20 | 0.79 |
| ▸ | PRKAA2 | P54646 | 10/20 | 0.79 |
| ▸ | PRKAA1 | Q13131 | 10/20 | 0.79 |
| ▸ | PRKAG3 | Q9UGI9 | 10/20 | 0.79 |
| ▸ | PRKAG2 | Q9UGJ0 | 10/20 | 0.79 |
| ▸ | PRKAB1 | Q9Y478 | 10/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519050 | 0.90 | CYP3A4 (0.70) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10269264 | 0.90 | CYP3A4 (0.70) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL519049 | 0.90 | CYP3A4 (0.70) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL519051 | 0.90 | CYP3A4 (0.70) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15171706 | 0.90 | CYP3A4 (0.80) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15171873 | 0.89 | PRKAB2 (0.63) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL518517 | 0.89 | PRKAA2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL518428 | 0.89 | PRKAA2 (0.79) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL517986 | 0.88 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL517920 | 0.88 | PRKAA2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAB2 5/4885PRKAG1 1/4885PRKAA2 7/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PRKAB2 5/4885PRKAG1 1/4885PRKAA2 7/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PRKAB2 5/4885PRKAG1 1/4885PRKAA2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.